Amir Eftekhari Milani1, Narges Hassanpoor2, Mohammadreza Mousavi Mirkala1, Arash Taheri1, Ali Golizade3, Mohamad Reza Niyousha4,5. 1. Retina and Vitreous Service, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Retina and Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. 3. Tabriz University of Medical Sciences, Tabriz, Iran. 4. Retina and Vitreous Service, Nikookari Eye Hospital, Tabriz University of Medical Sciences, Tabriz, Iran. mreza63neusha@gmail.com. 5. Eye Research Center, Nikookari Eye Hospital, Abbasi Street, Tabriz, 5154645395, Iran. mreza63neusha@gmail.com.
Abstract
PURPOSE: To compare type I retinopathy of prematurity (ROP) with aggressive posterior retinopathy of prematurity (AP-ROP) regarding risk factors, complications and treatment outcomes. METHODS: A prospective cohort approach was applied on premature newborns diagnosed as type I ROP and AP-ROP. An intravitreal injection of bevacizumab (Avastin®) was given to each patient. Demographic features such as gestational age, birth weight, age at the initial injection, involved eye, treatment response, relapses and need to extra interventions were compared. RESULTS: Seventy-seven patients underwent an initial intravitreal injection of bevacizumab (IVB), and 108 eyes were type I ROP and 30 eyes were AP-ROP. There was no significant difference in birth weight and gestational age between two groups. ROP relapsed in eight eyes of four patients with AP-ROP (26.6%), of which six eyes of three patients received re-injection of bevacizumab, and two eyes of one patient underwent a laser treatment. Recurrence occurred in two eyes of one patient with type I ROP (1.8%), which were treated by laser. CONCLUSION: Bilateral eye involvement, relapse and retreatment (IVB, laser and surgical intervention) are more frequent in AP-ROP than type I ROP even when treated with intravitreal bevacizumab injection.
PURPOSE: To compare type I retinopathy of prematurity (ROP) with aggressive posterior retinopathy of prematurity (AP-ROP) regarding risk factors, complications and treatment outcomes. METHODS: A prospective cohort approach was applied on premature newborns diagnosed as type I ROP and AP-ROP. An intravitreal injection of bevacizumab (Avastin®) was given to each patient. Demographic features such as gestational age, birth weight, age at the initial injection, involved eye, treatment response, relapses and need to extra interventions were compared. RESULTS: Seventy-seven patients underwent an initial intravitreal injection of bevacizumab (IVB), and 108 eyes were type I ROP and 30 eyes were AP-ROP. There was no significant difference in birth weight and gestational age between two groups. ROP relapsed in eight eyes of four patients with AP-ROP (26.6%), of which six eyes of three patients received re-injection of bevacizumab, and two eyes of one patient underwent a laser treatment. Recurrence occurred in two eyes of one patient with type I ROP (1.8%), which were treated by laser. CONCLUSION: Bilateral eye involvement, relapse and retreatment (IVB, laser and surgical intervention) are more frequent in AP-ROP than type I ROP even when treated with intravitreal bevacizumab injection.
Entities:
Keywords:
Aggressive posterior ROP; Bevacizumab; Cohort; Laser; Relapse; Treatment outcome; Type I ROP
Authors: Brian A Darlow; Jolie L Hutchinson; David J Henderson-Smart; Deborah A Donoghue; Judy M Simpson; Nicholas J Evans Journal: Pediatrics Date: 2005-04 Impact factor: 7.124
Authors: María A Martínez-Castellanos; Shulamit Schwartz; Myriam L Hernández-Rojas; Veronica A Kon-Jara; Gerardo García-Aguirre; José L Guerrero-Naranjo; R V Paul Chan; Hugo Quiroz-Mercado Journal: Retina Date: 2013-02 Impact factor: 4.256
Authors: Simona D Nicoară; Anne C Ștefănuţ; Constanta Nascutzy; Gabriela C Zaharie; Laura E Toader; Tudor C Drugan Journal: Med Sci Monit Date: 2016-04-10